ADC · HER2+ 유방암 | 바이오모아

ADCSFDAFDABiologicFundación Pública Andaluza para…Deruxtecan-Dlnk Quantificat…Phase 3

Datopotamab deruxtecan (Datopotamab deruxtecan)

Breast Cancer; Metastatic Breast Cancer · Lung Cancer

#LungCancer#ADC#Phase3#FDA승인#항체약물접합체+5

효능 ORR 79%임상시험 44상태 RECRUITING

ADCSFDAFDABiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#FDA승인#항체약물접합체+4

효능 ORR 71.7%임상시험 23상태 RECRUITING

ADCSHotBiologicRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5

효능 ORR 69.7%임상시험 106상태 RECRUITING

ADCBBiologicGileadaxisPhase 3

sacituzumab govitecan (Trodelvy)

Breast Cancer; Metastatic Breast Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 44%임상시험 87상태 RECRUITING

ADCBBiologicMerck Sharp & Dohme LLCPhase 2

Cytoxan (Cytoxan)

Multiple Myeloma, Refractory · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 95%임상시험 73상태 RECRUITING

ADCBiologicSpanish Breast Cancer Research …sPhase 2

Taxotere (Taxotere)

Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#인기#항체약물접합체+4

효능 ORR 88.1%임상시험 68상태 RECRUITING

ADCBiologicHoffmann-La RochePhase 2

Xeloda (Xeloda)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#인기#항체약물접합체+2

효능 ORR 30%임상시험 65상태 RECRUITING

ADCBiologicHoffmann-La RochePhase 2

Empagliflozin (Empagliflozin)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#인기#항체약물접합체+2

임상시험 61상태 RECRUITING

ADCBiologicPfizerderuxtecan and tucatinibPhase 3

Tucatinib (Tucatinib)

Dynamic Tumor Resistance; Metastatic Colorectal Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 100%임상시험 57상태 RECRUITING

ADCBiologicRochesPhase 1

trastuzumab (Herceptin, trastuzumab-MCC-DM1)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase1#인기#항체약물접합체+3

효능 ORR 69.7%임상시험 56상태 ACTIVE

ADCBiologicJiangsu HengRui Medicine Co., L…Phase 2

Famitinib (Famitinib)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5

임상시험 53상태 RECRUITING

ADCBiologicAstraZenecaderuxtecan or sacituzumab g…Phase 2

Capivasertib (Capivasertib)

Metastatic Breast Cancer · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 56.5%임상시험 50상태 RECRUITING

ADCBiologicstaleGBG Forschungs GmbHPhase 2

Inavolisib (Inavolisib)

HER2-positive Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 11.5%임상시험 31상태 RECRUITING

ADCBiologicstaleInstitut Claudius RegaudApproved

Pharmacokinetics blood samples (Pharmacokinetics blood samples)

Locally Advanced or Metastatic Breast Cancers · Locally Advanced or Metastatic Breast Ca

#LocallyAdvancedorMetastaticBreas#ADC#Approved#항체약물접합체#antibody-drug-conjugate+1

효능 ORR 91.2%임상시험 31상태 RECRUITING

ADCBiologicstaleChipscreen Biosciences, Ltd.Phase 3

taxane drug (taxane drug)

HER2-positive Metastatic Breast Cancer; First-line Treatment · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3

효능 ORR 81.1%임상시험 31상태 RECRUITING

ADCBiologicstaleJiangsu HengRui Medicine Co., L…Phase 2

pyrotinib plus capecitabine (pyrotinib plus capecitabine)

Metastatic Breast Cancer in the Brain · Metastatic Breast Cancer in the Brain

#MetastaticBreastCancerintheBrain#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 30상태 RECRUITING

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Lung Neoplasm Malignant · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 56%임상시험 28상태 RECRUITING

ADCBiologicstaleShanghai Hengrui Pharmaceutical…Phase 2

SHR-A2102 (SHR-A2102)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 25상태 RECRUITING

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

U3-1402 (U3-1402)

Metastatic Breast Cancer; Advanced Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 56%임상시험 24상태 ACTIVE

ADCBiologicstaleByondis B.V.Phase 3

trastuzumab (Herceptin, vic-, (vic-)trastuzumab duocarmazine)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1

효능 ORR 27.8%임상시험 23상태 ACTIVE

1 / 2 페이지

← 이전다음 →

갱신 기록 없음 · 14일 주기 · 방문 16 / 568